Novo Nordisk reports findings of HERO haemophilia study
11 July 2012 11:30 in Pharmaceutical Company Product News
Novo Nordisk has reported the first results from the HERO study, which examines the psychosocial aspects of living with haemophilia.
Initial findings from the HERO (Haemophilia Experiences, Results and Opportunities) research programme, which is supported by Novo Nordisk, will be presented at this week's World Federation of Haemophilia 2012 World Congress.
The study has discovered that eight out of ten people with haemophilia think they have experienced a negative impact on their professional life, with one in five believing they have lost a job because of the genetic blood clotting disorder.
"Psychosocial issues can still be a challenge for people with haemophilia, for example societal stigma," said Alfonso Iorio, Professor at the Department of Clinical Epidemiology and Biostatics at McMaster University in Canada and member of the HERO International Advisory Board.
He added that the study will provide "much-needed evidence to support advocating for better comprehensive haemophilia care".
Haemophilia A affects roughly one in every 5,000 males, approximately 30 percent of whom have no family history.
Other news stories from 11/07/2012
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
